Brokers Issue Forecasts for ResMed’s Q2 Earnings (NYSE:RMD)

ResMed Inc. (NYSE:RMD) – Equities research analysts at Zacks Research raised their Q2 2025 earnings estimates for ResMed in a research report issued on Wednesday, January 29th. Zacks Research analyst R. Department now forecasts that the medical equipment provider will post earnings of $2.27 per share for the quarter, up from their prior estimate of $2.26. The consensus estimate for ResMed’s current full-year earnings is $9.35 per share. Zacks Research also issued estimates for ResMed’s Q3 2025 earnings at $2.30 EPS, Q4 2025 earnings at $2.37 EPS, FY2025 earnings at $9.13 EPS, Q1 2026 earnings at $2.27 EPS, Q2 2026 earnings at $2.34 EPS, Q3 2026 earnings at $2.49 EPS, Q4 2026 earnings at $2.49 EPS, FY2026 earnings at $9.58 EPS, Q2 2027 earnings at $2.57 EPS and FY2027 earnings at $10.50 EPS.

Several other equities research analysts have also weighed in on RMD. JPMorgan Chase & Co. increased their target price on ResMed from $270.00 to $286.00 and gave the stock an “overweight” rating in a research report on Friday. StockNews.com upgraded shares of ResMed from a “hold” rating to a “buy” rating in a research report on Tuesday, October 15th. The Goldman Sachs Group started coverage on shares of ResMed in a report on Thursday, January 16th. They issued a “buy” rating for the company. Royal Bank of Canada boosted their target price on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Finally, Robert W. Baird increased their price target on ResMed from $280.00 to $283.00 and gave the company an “outperform” rating in a research note on Friday, October 25th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, ResMed currently has an average rating of “Moderate Buy” and a consensus target price of $244.73.

ResMed Stock Down 8.1 %

Shares of ResMed stock opened at $236.66 on Friday. The stock has a market capitalization of $34.74 billion, a price-to-earnings ratio of 31.35, a PEG ratio of 1.83 and a beta of 0.70. ResMed has a twelve month low of $170.56 and a twelve month high of $263.05. The company has a current ratio of 2.92, a quick ratio of 1.91 and a debt-to-equity ratio of 0.13. The business’s 50 day simple moving average is $240.32 and its 200-day simple moving average is $235.99.

ResMed (NYSE:RMD) last released its earnings results on Thursday, January 30th. The medical equipment provider reported $2.43 earnings per share for the quarter, beating the consensus estimate of $2.29 by $0.14. ResMed had a net margin of 23.15% and a return on equity of 25.53%.

ResMed Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Shareholders of record on Thursday, February 13th will be issued a $0.53 dividend. This represents a $2.12 annualized dividend and a dividend yield of 0.90%. The ex-dividend date of this dividend is Thursday, February 13th. ResMed’s payout ratio is 28.08%.

Insider Activity

In other news, Director Witte Jan De sold 796 shares of the company’s stock in a transaction on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the transaction, the director now directly owns 6,723 shares of the company’s stock, valued at approximately $1,672,749.63. This represents a 10.59 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Peter C. Farrell sold 2,000 shares of the stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $248.74, for a total value of $497,480.00. Following the completion of the transaction, the director now owns 83,204 shares in the company, valued at $20,696,162.96. This represents a 2.35 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 11,030 shares of company stock worth $2,702,687 over the last 90 days. 0.71% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the business. Global Retirement Partners LLC boosted its stake in ResMed by 50.8% during the fourth quarter. Global Retirement Partners LLC now owns 582 shares of the medical equipment provider’s stock worth $133,000 after buying an additional 196 shares in the last quarter. Convergence Investment Partners LLC acquired a new stake in ResMed during the fourth quarter valued at approximately $1,026,000. Bfsg LLC grew its stake in shares of ResMed by 2.3% in the 4th quarter. Bfsg LLC now owns 17,562 shares of the medical equipment provider’s stock valued at $4,016,000 after purchasing an additional 395 shares during the period. Atria Wealth Solutions Inc. acquired a new position in shares of ResMed in the 4th quarter worth approximately $601,000. Finally, Venturi Wealth Management LLC lifted its position in shares of ResMed by 59.8% during the 4th quarter. Venturi Wealth Management LLC now owns 545 shares of the medical equipment provider’s stock worth $125,000 after buying an additional 204 shares during the period. 54.98% of the stock is currently owned by institutional investors and hedge funds.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.